Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMT-151 |
| Synonyms | |
| Therapy Description |
AMT-151 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against folate receptor alpha (FRa) linked to an undisclosed cytotoxic agent, which potentially leads to decreased proliferation of tumor cells expressing FRa (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMT-151 | AMT 151|AMT151 | FOLR1-targeted Therapy 24 | AMT-151 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against folate receptor alpha (FRa) linked to an undisclosed cytotoxic agent, which potentially leads to decreased proliferation of tumor cells expressing FRa (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Unknown status | AUS | 1 |